The Real Economy Blog

Economic News from RSM

Home > Health care > 5 things to know in life sciences: Week of April 25, 2022

5 things to know in life sciences: Week of April 25, 2022

by , , and

5 things to know in life sciences

This week we highlight a bold move to continue clinical trial progress, how the contract research organization industry perceives the state of biotech funding, and machine learning and the fight against long COVID-19. We also weigh COVID-19 risks and a White House event, and the Food and Drug Administration’s first approval of a treatment for young children. Each week we highlight five things you need to know about in the life sciences industry. Here’s the latest.

Moving clinical trial participants out of Ukraine to maintain progress

In a move we haven’t seen yet and an effort to maintain clinical trial progress for its multiple sclerosis patients in Ukraine, Sanofi has moved its MS patients out of Ukraine and into areas west of the country. About 11% of Sanofi’s MS study sites are in Ukraine.

Biotech funding and IQVIA’s first-quarter earnings call

First-quarter earnings calls are still taking place. With some nervousness surrounding biotech funding as a result of this year’s market slowdown, we thought it might be beneficial to note that IQVIA’s earnings call indicated double-digit request-for-proposal growth from emerging biopharmas. This sentiment appears to be consistent across the industry. We are continuing to monitor this trend.

Machine learning and the fight to understand long COVID-19

In this article, researchers discuss additional machine learning applications in their long COVID-19 research, challenges and what they hope to accomplish over time.

Biden to attend White House correspondents’ dinner amid COVID-19 precautions

President Biden plans to attend the White House Correspondents’ Association dinner this year. This is the first time a sitting president has attended since 2016. This article explores the reality that COVID-19 is still a challenge in the U.S. and the important risks to consider, even for a president.

FDA approves first COVID-19 treatment for young children

The FDA recently expanded the approval of the COVID-19 treatment Veklury (remdesivir) to include pediatric patients 28 days of age and older, weighing approximately 7 pounds or more, who test positive for the virus. Patients would have to be already hospitalized or at high risk for hospitalization. Veklury is the first approved COVID-19 treatment for children less than 12 years of age.

Related posts

About Justin Culbertson

Justin has more than 10 years of experience serving publicly traded and privately held companies through technical accounting and financial reporting services. He focuses on clinical research organizations and similar service organizations in the constantly evolving life sciences industry. He has previously advised clients in the areas of new standard implementation, external audit, internal audit, risk management, mergers and acquisitions, process design and improvement, and internal and external financial reporting. He is also a member of RSM’s life sciences national industry leadership team.

In May 2021, Justin was selected as a senior analyst in RSM’s cutting edge industry eminence program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves.

About Steve Kemler

Steve manages the Philadelphia market NetSuite team and provides NetSuite consulting services to a variety of clients in industries including life sciences, technology and wholesale distribution. Steve leads projects that require complex integrations, customizations and complex finance requirements.

As a member of RSM’s life sciences team, Steve consistently supports clients in the industry across the country. He also participates in the PACT MedTech series and is involved in multiple regional life sciences initiatives.

In May 2020, Steve was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves.

About Adam Lohr

Adam is an audit partner and life sciences senior analyst in RSM's cutting-edge Industry Eminence Program. In addition to providing assurance services to his clients, he sits on RSM’s national life sciences team and leads the San Diego office life science practice.

His senior analyst responsibilities include advising the firm’s life sciences care clients and client servers as they work to navigate the rapidly changing industry environment. Adam regularly writes, presents and advises on capital markets, digital transformation, policy and other issues transforming life sciences. He is an instructor at the regional and national level, and is experienced in the application of ASC 606 revenue recognition for the technology and consumer products industries.

Adam has over 12 years of accounting and finance experience, serving private equity-backed and private closely held companies in the middle market. He specializes in providing financial audit services and helping clients respond to technical, regulatory and economic changes that impact their business.

About David Stuart

David has more than eight years of corporate finance and capital markets experience supporting debt and equity transactions for various industries including technology, telecommunications, life sciences, renewable energy and consumer products. His experience includes negotiating and facilitating transaction closings for private equity, venture capital and financial institutions across North America.

In May 2020, David was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves.

The Real Economy Blog